Nikiphorou Elena, Jacklin Hannah, Bosworth Ailsa, Jacklin Clare, Kiely Patrick
Department of Inflammation Biology, Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, Faculty of Life Sciences & Medicine.
National Rheumatoid Arthritis Society, Maidenhead.
Rheumatol Adv Pract. 2021 Jan 5;5(1):rkaa080. doi: 10.1093/rap/rkaa080. eCollection 2021.
The aim was to reveal the everyday impact of living with RA in people not treated with advanced therapies (i.e. biologic or targeted synthetic DMARDs).
People with RA, with disease duration >2 years, not currently treated with advanced therapies, completed an online survey promoted by the National Rheumatoid Arthritis Society. Items covered demographics, current treatment, RA flare frequency, the Rheumatoid Arthritis Impact of Disease (RAID) tool and questions reflecting work status and ability. Descriptive and multivariable regression analyses were performed.
There were 612 responses from patients having a mean age of 59 years, 88% female, 37.7% with disease duration 2-5 years and 27.9% with disease duration 5-10 years. In the last year, 90% reported an RA flare, with more than six flares in 23%. A RAID patient acceptable state was recorded in 12.4%. Each of the seven domains was scored in the high range by >50% respondents; 74.3% scored sleep problems and 72% fatigue in the high range. A need to change working hours was reported by 70%. Multivariable analyses revealed that increasing difficulties with daily physical activities, reduced emotional and physical well-being in the past week were all significantly associated with pain, number of flares and ability to cope ( < 0.005). The RAID score was significantly predictive of the number of flares.
Patients not currently treated with advanced therapies experience profound difficulties in everyday living with RA, across a broad range of measures. We advocate that patient-reported measures be used to facilitate holistic care, addressing inflammation and other consequences of RA on everyday life.
本研究旨在揭示未接受先进疗法(即生物制剂或靶向合成改善病情抗风湿药)治疗的类风湿关节炎(RA)患者的日常影响。
病程超过2年且目前未接受先进疗法治疗的RA患者完成了由英国国家类风湿关节炎协会发起的一项在线调查。调查项目包括人口统计学信息、当前治疗情况、RA病情 flare 频率、类风湿关节炎疾病影响(RAID)工具以及反映工作状态和能力的问题。进行了描述性分析和多变量回归分析。
共收到612份患者回复,患者平均年龄59岁,女性占88%,病程2 - 5年的患者占37.7%,病程5 - 10年的患者占27.9%。在过去一年中,90%的患者报告有RA病情 flare,其中23%的患者病情 flare 超过6次。记录到12.4%的患者处于RAID患者可接受状态。超过50%的受访者在七个领域中的每个领域得分都处于较高范围;74.3%的受访者在睡眠问题方面得分较高,72%的受访者在疲劳方面得分较高。70%的患者报告需要改变工作时间。多变量分析显示,日常身体活动困难增加、过去一周情绪和身体健康状况下降均与疼痛、病情 flare 次数及应对能力显著相关(<0.005)。RAID评分可显著预测病情 flare 次数。
目前未接受先进疗法治疗的RA患者在日常生活中面临诸多严重困难,涉及广泛的衡量指标。我们主张使用患者报告的指标来促进整体护理,解决RA对日常生活的炎症及其他影响。